Related Experiment Video
Updated: May 18, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and
Rintaro Hashizume1, Ivan Smirnov, Sharon Liu
1Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143-0520, USA.
Abstract:
Diffuse intrinsic pontine gliomas arise almost exclusively in children, and despite advances in treatment, the majority of patients die within 2 years after initial diagnosis. Because of their infiltrative nature and anatomic location in an eloquent area of the brain, most pontine gliomas are treated without a surgical biopsy. The corresponding lack of tissue samples has resulted in a limited understanding of the underlying genetic and molecular biologic abnormalities associated with pontine gliomas, and is a substantial obstacle for the preclinical testing of targeted therapeutic agents for these tumors. We have established a human glioma cell line that originated from surgical biopsy performed on a patient with a pontine glioma. To insure sustainable in vitro propagation, tumor cells were modified with hTERT (human telomerase ribonucleoprotein reverse transcriptase), and with a luciferase reporter to enable non-invasive bioluminescence imaging. The hTERT modified cells are tumorigenic in athymic rodents, and produce brainstem tumors that recapitulate the infiltrative growth of brainstem gliomas in patients.
Insights
Researchers developed a new human glioma cell line from a pontine glioma biopsy. This cell line, modified for sustained growth and imaging, effectively models diffuse intrinsic pontine gliomas in preclinical studies.
Area of Science:
- Pediatric neuro-oncology
- Cancer biology
- Genetics
Background:
- Diffuse intrinsic pontine gliomas (DIPG) are aggressive pediatric brain tumors with poor prognosis.
- Limited tissue availability hinders understanding of DIPG's genetic and molecular basis.
- Lack of DIPG models impedes preclinical testing of targeted therapies.
